{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T09:45:19Z","timestamp":1785923119398,"version":"3.56.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess the utility of fluorodeoxyglucose (FDG) PET-based myocardial viability in patients with left ventricular (LV) dysfunction, its role in guiding therapeutic decision-making, and its impact on patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retro-prospective study included 70 patients of coronary artery disease, with myocardial infarction and LV dysfunction [left ventricular ejection fraction (LVEF)\u2005\u2264\u200535%]. All patients underwent rest single-photon emission computerized tomography myocardial perfusion imaging and FDG PET cardiac viability imaging. Viability was assessed qualitatively and quantitatively as the percentage of viable hibernating myocardium. Patients were categorized as having predominantly viable myocardium (\u22657% viable hibernating LV myocardium) or predominantly scarred myocardium (&lt;7%). Management decisions included surgical revascularization or medical therapy. Outcomes at 6-month followup included improvement in LVEF (\u22655%), cardiac events, and cardiac-related death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During follow up, two patients died of noncardiac causes. Among 68 patients (mean LVEF 25.58%), 88.2% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u200560) had predominantly viable myocardium and 11.8% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u20058) had scarred myocardium on FDG PET cardiac scan. Of viable patients, 89.8% (44\/49) undergoing revascularization showed LVEF improvement at least 5% vs. 45.5% (5\/11) medically managed (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.002784). Cardiac events occurred in 4.1% vs. 27.3%, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.039). No significant association was found between treatment type and outcomes in the scarred group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.464).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FDG PET-based myocardial viability assessment can potentially play a role in guiding therapeutic decision-making in patients with LV dysfunction by identifying those with predominantly viable hibernating myocardium who are more likely to benefit from revascularization and have better outcomes in terms of improved LV function and fewer cardiac events compared to those managed medically.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002168","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:01:03Z","timestamp":1777363263000},"page":"1081-1087","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Role of fluorodeoxyglucose positron emission tomography scan in assessing the extent of myocardial viability in patients with left ventricular dysfunction and its impact on patient outcome"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1456-8130","authenticated-orcid":false,"given":"Janpreet","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine and PET-CT, P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and PET-CT, P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvika","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and PET-CT, P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Shivdasani","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and PET-CT, P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"R1-20260805","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ihj.2015.11.017","article-title":"Role of PET-CT in the assessment of myocardial viability in patients with left ventricular dysfunction.","volume":"68","author":"Srivatsava","year":"2016","journal-title":"Indian Heart J"},{"key":"R2-20260805","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.3390\/jcm14145002","article-title":"Cardiac imaging in the diagnosis and management of heart failure.","volume":"14","author":"Chaudhari","year":"2025","journal-title":"J Clin Med"},{"key":"R3-20260805","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/HCO.0000000000000652","article-title":"Assessment of myocardial viability by PET.","volume":"34","author":"Al-Mallah","year":"2019","journal-title":"Curr Opin Cardiol"},{"key":"R4-20260805","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/jamacardio.2023.3803","article-title":"Viability and outcomes with revascularization or medical therapy in ischemic ventricular dysfunction: a prespecified secondary analysis of the REVIVED-BCIS2 trial.","volume":"8","author":"Perera","year":"2023","journal-title":"JAMA Cardiol"},{"key":"R5-20260805","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0735-1097(02)01726-6","article-title":"Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis.","volume":"39","author":"Allman","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R6-20260805","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.3390\/jcm14155529","article-title":"The role of imaging modalities in estimating myocardial viability: a narrative review.","volume":"14","author":"Modak","year":"2025","journal-title":"J Clin Med"},{"key":"R7-20260805","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"R8-20260805","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jacc.2021.07.004","article-title":"Myocardial viability assessment before surgical revascularization in ischemic cardiomyopathy: JACC review topic of the week.","volume":"78","author":"Panza","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R9-20260805","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1007\/s12350-020-02460-2","article-title":"Evolving use of PET viability imaging.","volume":"29","author":"de Oliveira Brito","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"R10-20260805","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jcmg.2009.02.017","article-title":"Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial.","volume":"2","author":"D\u2019Egidio","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"R11-20260805","doi-asserted-by":"crossref","first-page":"e011284","DOI":"10.1161\/CIRCINTERVENTIONS.121.011284","article-title":"Change in left ventricular ejection fraction with coronary artery revascularization and subsequent risk for adverse cardiovascular outcomes.","volume":"15","author":"Velagaleti","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"R12-20260805","doi-asserted-by":"crossref","first-page":"e002962","DOI":"10.1161\/CIRCHEARTFAILURE.115.002962","article-title":"Changes in left ventricular ejection fraction predict survival and hospitalization in heart failure with reduced ejection fraction.","volume":"9","author":"Breathett","year":"2016","journal-title":"Circ Heart Fail"},{"key":"R13-20260805","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1056\/NEJMoa1100358","article-title":"Myocardial viability and survival in ischemic left ventricular dysfunction.","volume":"364","author":"Bonow","year":"2011","journal-title":"N Engl J Med"},{"key":"R14-20260805","doi-asserted-by":"crossref","first-page":"e004331","DOI":"10.1161\/CIRCIMAGING.115.004331","article-title":"Long-term follow-up of outcomes with F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction secondary to coronary disease.","volume":"9","author":"McArdle","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"R15-20260805","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12410-011-9074-8","article-title":"Radionuclide imaging of viable myocardium: is it underutilized?","volume":"4","author":"Mylonas","year":"2011","journal-title":"Curr Cardiovasc Imaging Rep"},{"key":"R16-20260805","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4414\/cvm.2013.00189","article-title":"Assessment of myocardial viability after the STICH-trial: still viable?","volume":"16","author":"Valenta","year":"2013","journal-title":"Cardiovasc Med"},{"key":"R17-20260805","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCIMAGING.112.000138","article-title":"Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium.","volume":"6","author":"Ling","year":"2013","journal-title":"Circ Cardiovasc Imaging"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T09:00:16Z","timestamp":1785920416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002168","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"2026-01-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}